The IDF congress is the only truly global meeting bringing together thousands of delegates, close to 300 high-level speakers and representatives from over 24o national diabetes associations from more than 160 countries and territories.
The IDF Congress attracts healthcare professionals, diabetes associations, policy-makers and companies to share the latest findings in diabetes research and best practice.
Who attends the IDF Congress?
Attendees of the IDF congress come from 180 countries and very diverse backgrounds
Healthcare professionals (physicians, nurses, general practitioners, dieticians, diabetes educators...)
Research scientists (university professors, researchers...)
Non-profit organisations (diabetes youth organisations, professional organisations of health carers, medical and scientific organisations...)
IDF members and other related associations
Health policy makers
Why you should not missout?
The IDF Congress provides a unique and unbiased environment for personal and individual interaction with international healthcare professionals.
The exhibition serves as an acknowledged platform to present, explain and inform about services and products and is an integral part of the IDF Congress.
The IDF Congress allows you to exchange with the diabetes community at large and to address medical doctors and specialised healthcare professionals face-to-face.
The IDF Congress strongly supports the educational purpose of the meeting and enhances the congress experience for delegates.
How to secure your participation?
The exhibition will be held in the Bangkok International Trade and Exhibition Center BITEC in Hall 98, offering 8.400 m² column free space of 16m height with full rigging for commercial and non-profit organisations to showcase their services and products.
Contact us for a comprehensive overview of exhibition, satellite symposia and sponsorship opportunities and to receive a copy of the IDF Congress 2021 Industry Prospectus.
The congress centre is directly connected to all congress hotel in the city via the modern and fast BTS Skytrain (Station Bang Na) and has successfully hosted a variety of international conventions and welcomed numerous delegates from around the world.
BITEC offers several large scale, multi-purpose event halls and comprehensive exhibition services. With a total event space of 70,000 sq. m., the purpose-built facility addresses the needs of convention organisers, delegates and exhibitors for easy accessibility, quality and professional services. The column-free venue accommodates up to 40,000 delegates within fully flexible spaces that include 10 expansive exhibition halls, 6 grand convention halls and 28 breakout meeting rooms.
Over 460 million people around the world are currently living with diabetes. Many, particularly in low and middle-income countries, do not have the means to access the medications and supplies they need to manage their condition to avoid complications.
People with diabetes need uninterrupted access to medicines and care. They need healthy food and a safe space to exercise. Caring for diabetes becomes even more difficult when disaster strikes and people are forced to flee. In these difficult circumstances, people with diabetes often struggle to manage their condition and are at increased risk of life-threatening complications.
Since 2009, the International Diabetes Federation has collaborated with the humanitarian organisation Direct Reliefto provide access to life-sustaining medication and monitoring to vulnerable populations. The supplies include insulin, needles & syringes, blood glucose meters & strips, and specialized diagnostic equipment.
Direct Relief is active in more than 80 countries, with a mission to improve the health and lives of people affected by poverty or emergencies – without regard to politics, religion, or ability to pay. Their assistance programmes are tailored to the particular circumstances and needs of the world's most vulnerable and at-risk populations and their relationships with prominent regional and global associations and agencies enable them to respond to crisis situations in the most timely and effective manner possible.
Direct Relief works closely with all three global insulin manufacturers and is currently the world’s largest provider of humanitarian insulin. Direct Relief’s facility has the refrigeration capacity to store specialty medicines (up to 300 pallets of cold- chain product) for distribution to over 100 countries around the world.
Temperature-sensitive medicines like insulin are shipped in specialised packaging that maintains a constant temperature range for up to 120 hours. To ensure and verify that temperature has been maintained throughout the transit process, temperature-data loggers are inserted into each package to record the internal temperature of the shipment, to be confirmed within range before the product is released for use by those who need them.
In 2019, IDF and Direct Relief began a pilot collaboration to encourage healthcare manufacturers to donate diabetes-related medications and supplies to help address gaps in diabetes care during times of emergency and or crisis situations. The collaboration has resulted in the donation and distribution of over 5 million tablets of oral diabetes medications, tens of thousands of vials of insulin, and diabetes-related supplies to numerous countries, including the Bahamas, Bolivia, Democratic Republic of Congo, Ethiopia, Kurdistan, Malawi, North Korea, Republic of Congo, Syria, Venezuela, and Zimbabwe.
IDF and Direct Relief are inviting healthcare companies that manufacture diabetes-related medicines, enabling technologies, and diagnostic products to support this programme with regular donations to assist countries and regions impacted by emergency and disaster situations. IDF will help identify and work with its members in those affected regions that need support to ensure an appropriate and rapid response.
For more information about the initiative and how to support it, please contact:
The scientific programme will cover a wide range of topics relevant to diabetes. Across eight parallel streams, it will address the basic science and biology of diabetes, the development and application of new drugs, therapies and technologies, the latest information from clinical trials, the burden of diabetes and its complications in populations around the globe, the prevention of diabetes, and policy and advocacy issues critical to addressing the diabetes pandemic.
A particular focus on issues relating to women and to the voice of people with diabetes will be a feature of the programme.
Speakers will include world-leading experts, early career researchers, and people at the coalface who work with or live with diabetes. A range of different formats from lectures to debates and workshops will present cutting-edge findings and state-of-the-art reviews. The highly interactive environment will encourage exchanges of views and the development of new ideas and collaborations.
The IDF 2021 Programme Committee
Meet the stream leads of the IDF Congress 2021
Programme Committee Chair: Jonathan Shaw, Australia
Jonathan is Deputy Director at Melbourne’s Baker Heart and Diabetes Institute. He is also an endocrinologist, Chair of the Diabetes Advisory Group to the Australian Institute of Health & Welfare and council member of the Australian Diabetes Society.
Vice Chair: João Valente Nabais, Portugal
João Valente Nabais PhD is Assistant Profesor with Habilitation at University of Evora (Portugal). Diagnosed with type 1 diabetes in 1981, João has been actively involved in the field of diabetes through his work at national and international level.
Basic and Translational Science Stream Lead: Paula Macedo, Portugal
Paula Macedo is currently Professor at the NOVA Medical School, NOVA University in Lisbon, and at the Department of Medical Sciences Universidade Aveiro, Portugal.
Diabetes Complications and Comorbidities Stream Lead: Andrea Luk
Andrea Luk is currently the Associate Professor of the Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR.
Diabetes in Women Stream Lead: Maria Inês Schmidt
Maria Inês Schmidt MD, PhD is an endocrinologist and epidemiologist trained at the John Hopkins Hospital and at the University of North Carolina.
Education and Integrated Care Stream Lead: Zilin Sun
Zilin Sun M.D., Ph.D., is Professor of Medicine and the Director of the Institute of Diabetes in Southeast University in Nanjing, China.
Epidemiology and Public Health Stream Lead: Ayesha Motala
Ayesha Motala is a specialist physician and currently Professor and Clinical Head in the Department of Diabetes and Endocrinology at Inkosi Albert Luthuli Central Hospital affiliated to the Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
Living with Diabetes Stream Lead: Sana Ajmal
Sana Ajmal is a seasoned diabetes advocate , with years of experience with various IDF programmes and activities, including Young Leaders in Diabetes, Diabetes Education Consultative Section, the World Diabetes Congress Program Committee and other international bodies.
Clinical, Therapeutic and Technology Research Stream Lead: Shashank Joshi
Shashank R. Joshi is the Chair of the Southeast Asian Region of IDF and Dean of the Indian College of Physicians from Mumbai, India. He is Past President of the Endocrine Society of India, RSSDI and many other societies in India and Asia.
Health Services and Policy Stream Lead: Niti Pall
Niti Pall is President of IDF Europe. She is Global Medical Director for KPMG and Senior Mobile Health Advisor for AXA. She also sits on the board of the Birmingham Women’s and Children’s Hospital. Niti is a senior Doctor who has deep expertise in primary care models and health benefit management across the world.
The IDF Congress 2021 welcomes original abstracts on subjects relevant to the eight programme streams. The online abstract submission is open from 14 April to 19 June 2021. Share your scientific work with a global audience of healthcare professionals following the Abstract submission guidelines.
Continuing Medical Education (CME)
Applications for Continuing Medical Education (CME) accreditation for physicians and other healthcare professionals will be presented to the national accreditation body and the European Accreditation Council for Continuing Medical Education (EACCME). EACCME credits are recognised by the American Medical Association towards the Physician’s Recognition Award (PRA). It is expected that the IDF Congress 2021 will be accredited with approximately 20 hours of CME credits. CME certificates will be available after the congress.
Abstract submission for the IDF Diabetes Complications Congress 2020 in Lisbon, Portugal is now closed. We thank the submitters and authors for their contributions. All abstracts are now under review and will be evaluated by our independent reviewers. All notifications on acceptance/rejection will be sent out on the 9th of September 2020.
Download our Advance Programme Call for Abstracts:
Submission mode: Abstract submission is only possible online. Abstracts submitted by post, fax or email will NOT be accepted. The online abstract submission module will NOT be available after 31 July 2020.
IDF congress profile: In order to submit an abstract, a congress profile must be created giving access to the online abstract submission module. The submitting author must ensure accurate contact details are entered. One or more abstracts can be submitted by logging into this congress profile.
Submitting author / presenting author: If the submitting author is not also the presenting author, the submitting author is responsible for informing the presenting author of all communications received regarding the abstract.
Presenting author registration: The presenting author must be registered by 27 September 2020. If the presenting author is not registered by this date, their abstract will be REMOVED from the programme.
Number of submissions: There can only be ONE presenting author per abstract. The same abstract CANNOT be submitted multiple times by listing different presenting authors. An unlimited number of abstracts can be submitted by an author.
Language: All abstracts must be submitted in English. Should English not be your first language, you may wish to have your abstract examined by a native English speaker prior to submission.
Accuracy of content: Submitted abstracts may be edited online up to the abstract submission deadline of 31 July 2020. Abstracts CANNOT be edited or revised in any way after the deadline. All accepted abstracts will be published as submitted by the authors. The responsibility for the submission of an accurate and precise abstract lies solely with the authors.
Originality of abstracts: Work published in peer-reviewed journals before 3 December 2020 should NOT be submitted to the IDF Diabetes Complications Congress 2020. Abstracts already presented at face-to-face meetings should also not be submitted. However, previously submitted work can be resubmitted provided there are new methods and/or findings.
Disclosure of interests: Any financial relationships with commercial entities related to the authors or products and processes described in the work must be correctly disclosed.
Regulatory approval: The submitting author confirms that local regulatory approval has been obtained as required by local laws.
Author consent: The submitting author declares all authors have read and approved the submitted work.
Copyright transfer: Authors must attest that their submitted work does not infringe any copyright legislation. Copyright for the publication of abstracts is automatically transferred to the International Diabetes Federation upon submission and acceptance of the regulations within the online submission module.
For rejected abstracts, the copyright reverts back to the authors.
Topic: There are various categories that have been defined for the abstract programme within the three streams. Ensure that you select the MOST relevant topic which BEST describes the content of your abstract. Categories are used for reviewing and indexing purposes.
Abstract title: The title is limited to 120 characters including spaces and should be brief and relevant. Special characters should NOT be used in your title but spelt out instead (e.g. α should be written as alpha, β as beta). Only use standard abbreviations and generic drug names in the title.
Authors: Only 12 authors and/or study groups can be listed. Only one institution can be entered per author.
The abstract structure is laid out under the headings Background, Aims, Method, Results and Discussion.
Font size and style will be automatically configured by the system.
Tables will be accepted in the submission field and count towards the character limit. The character deduction for tables is not fixed and will be generated by the character count shown below the submission field. Graphs, figures and photographs are NOT allowed.
The length of the abstract is limited to 500 words. Only the abstract body and any inserted tables count towards this word limit. The word count displayed beneath the submission field is final and indisputable.
Only commonly accepted abbreviations should be used (e.g. GDM, BMI, DM). Treatment groups or drug names should NOT be abbreviated. Less widely recognised abbreviations may be used if introduced on first usage (e.g. ambulatory blood pressure monitoring, ABPM).
Only approved and generic (non-proprietary) drug names should be used.
Do NOT enter the title, authors, or grant information into the abstract body but include any references at the end of the abstract.
Selection and notification process
Selection: All submitted abstracts undergo a review process by the Programme Committee. Accepted abstracts are selected for oral poster presentation or poster display. The Programme Committee reserves the right to accept or reject any submitted abstract and re-categorise any accepted abstract. The decision of the Programme Committee is final and irrevocable.
Notification: Notice of acceptance or rejection of submitted abstracts will be sent to the submitting authors by 9 September 2020. It is the responsibility of the submitting author to inform all other authors of the status of the abstract. A submitting author may also check their congress profile to see the status of the abstract.
Author Registration: Presenting authors of accepted abstracts MUST register for the congress by 27 September 2020. If the entire registration fee is not paid by the deadline, the abstract will be automatically withdrawn and will NOT be presented or published.
Late-breaking abstract policy
The IDF Diabetes Complications Congress 2020 will not be accepting late-breaking abstracts. All abstracts must be submitted during the regular submission period starting on 1 June and ending on 31 July 2020.